Celgene — Shareholder Meeting (May 2016)
19 slides from Celgene's shareholder meeting presentation, May 10, 2016
Slide 1: Additional 2016 Proxy Materials Celgene
Additional 2016 Proxy Materials Celgene (NASDAQ: CELG)
Slide 2: Forward Looking Statements and Adjusted Financial Information
Forward Looking Statements and Adjusted Financial Information 2 This presentation contains forward - looking statements, which are generally statements that are not historical facts . Forward - looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estima
Slide 3: Agenda
Agenda • Company Overview • Celgene Proposal to Amend the 2008 Equity Plan • Celgene Proposal to Ratify the By - Law Amendment on Forum Selection • Stockholder Proposal on Special Meetings • Stockholder Proposal on Proxy Access 3
Slide 4: We Are A Leading Global Biopharmaceutical Company
We Are A Leading Global Biopharmaceutical Company 4 Unique R&D Capability • Expertise in hematology, oncology, and immunology • Diverse technology platforms • Rich pipeline – 70 programs in preclinical development – 32 treatments in clinical trials – 24 pivotal / phase III programs underway • Operat
Slide 5: We Have a Strong 5-Year Financial Track Record
$1.89 $2.45 $2.98 $3.71 $4.71 2011 2012 2013 2014 2015 We Have a Strong 5 - Year Financial Track Record 5 $1.24 $1.31 $1.51 $1.65 $2.04 2011 2012 2013 2014 2015 Notes: 1) Net Product Sales adjusted for 2011, 2) CAGR calculated using 2010 to 2015, 3) Adjusted EPS is split - adjusted for 2011 - 2013.
Slide 6: Our Performance Has Led to Significant Value Creation
Our Performance Has Led to Significant Value Creation CELG NBI BTK COMP SPX 1 - year 7.1% 11.4% 10.9% 5.7% - 0.7% 3 - year 205.2% 147.4% 146.5% 65.8% 43.3% 5 - year 305.0% 264.9% 193.9% 88.8% 62.5% 10 - year 639.3% 348.0% 460.1% 127.1% 63.7% 6 Note: Periods are for calendar year; amounts based on qu
Slide 7: Operational Achievements Are Expected to Sustain Our Growth Profile Through 2020
Operational Achievements Are Expected to Sustain Our Growth Profile Through 2020 7 2015 2017E 2020E Net Product Sales ($B) 18% CAGR >$21 $9.2 $12.7 - $13 2015 2017E 2020E 23% CAGR >$13 $4.71 $6.75 - $7.00 Adjusted EPS ($) Key Operational Achievements x Executing Global Launches for Blockbuster Brand
Slide 8: Our Equity Plan Is a Critical Tool to Delivering on Our 2020 Financial Targets
Our Equity Plan Is a Critical Tool to Delivering on Our 2020 Financial Targets The primary purpose of the Plan is to enable us to attract, retain, and motivate key employees who are important to our success by aligning their interests with those of our stockholders: • Our Plan has broad participatio
Slide 9: The Plan Has Several Stockholder-Friendly Features
The Plan Has Several Stockholder - Friendly Features The Plan has several features designed to protect stockholder interests and promote effective corporate governance, including: • The Plan is administered by the Compensation Committee comprised solely of independent directors • Stock options have
Slide 10: We Are Requesting 17.5 Million Additional Shares for the Equity Plan
We Are Requesting 17.5 Million Additional Shares for the Equity Plan 10 Key Consideration for Stockholders: • We believe that without such approval we would lose a critical stockholder alignment feature of our compensation framework and would not be able to compete effectively in a biopharma market
Slide 11: Existing Stock Options Outstanding and Shares Available
11 Total % of Shares Outstanding Stock Options Outstanding, all plans (1) 75,990,781 9.8% Full - Value Awards Outstanding, all plans 7,894,683 1.0% Shares Available for Awards, all plans (2) (3) 35,834,888 4.6% 1) As of April 18, 2016, the range of the exercise prices of stock options outstanding un
Slide 12: Our Strong Performance Has Created a Significant Overhang with In-the-Money Options
Our Strong Performance Has Created a Significant Overhang with In - the - Money Options Year Granted (Calendar Year) Employee Options Outstanding Employee Options Exercisable Weighted Avg. Exercise Price Weighted Avg. Contractual Term (in years) Options Held by Current NEOs 2015 11,117,068 1,292,572
Slide 13: Proposal Five: Ratify Amendment to By-Laws on Forum Selection
Proposal Five: Ratify Amendment to the Company’s By - Laws on Forum Selection for Internal Corporate Claims 13 The Board recommends that stockholders VOTE FOR this proposal to ratify the Amendment to the Company’s by - laws adding a new Section 6.5 which provides that Internal Corporate Claims may o
Slide 14: Proposal Six: Stockholder Proposal on Right to Call a Special Meeting
Proposal Six: Stockholder Proposal Seeking By - Law Amendment Granting Stockholder’s the Right to Call a Special Meeting 14 An individual stockholder, John Chevedden , submitted Proposal Six requesting the Board to take the steps necessary to amend the by - laws and each appropriate governing docume
Slide 15: Proposal Seven: Stockholder Proposal for Proxy Access
Proposal Seven: Stockholder Proposal for Proxy Access 15 UAW Retiree Medical Benefits Trust submitted Proposal Seven requesting the Board to adopt and present for stockholder approval a 3%, 3 - Year proxy access by - law. After careful consideration, the Board has concluded that this stockholder pro
Slide 16: Conclusion
Conclusion We recommend stockholders vote: x FOR Proposal Three to amend our Stock Incentive Plan x FOR Proposal Five to ratify the by - law amendment on Forum Selection x AGAINST Proposal Six on Special Meetings x AGAINST Proposal Seven on Proxy Access 16
Slide 17: Additional 2016 Proxy Materials Celgene
Additional 2016 Proxy Materials Celgene (NASDAQ: CELG)
Slide 18: Reconciliation Tables
Reconciliation Tables 18 2015 2014 2013 2012 2011 2010 Net income attributable to Celgene - GAAP 1,602.0$ 1,999.9$ 1,449.9$ 1,456.2$ 1,318.1$ 880.5$ Before tax adjustments: Net product sales: Sales of products exited it to be exited: Pharmion (1) - - - - (5.4) (8.2) Abraxis (1) - - - - (21.3) (15.9)
Slide 19: Reconciliation Tables: Explanation of adjustments
Reconciliation Tables 19 Explanation of adjustments: (1) Exclude sales related to non-core former Pharmion Corp., or Pharmion, and Abraxis BioScience Inc., or Abraxis products to be divested. (2) Exclude the estimated impact of activities arising from the acquisition of Abraxis that are not related